Encapsulation of Exenatide in Poly-(d,l-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes

Exenatide once-weekly (EQW [2 mg s.c.]) is under development as monotherapy as an adjunct to diet and exercise or as a combination therapy with an oral antidiabetes drug(s) in adults with type 2 diabetes. This long-acting formulation contains the active ingredient of the original exenatide twice-dai...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: DeYoung, Mary Beth, MacConell, Leigh, Sarin, Viren, Trautmann, Michael, Herbert, Paul
Formato: Artigo
Lenguaje:Inglês
Publicado: Mary Ann Liebert, Inc. 2011
Materias:
Reviews
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3202891/
https://ncbi.nlm.nih.gov/pubmed/21751887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/dia.2011.0050
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares